A new urine-based tumor DNA (utDNA) test shows promise in predicting treatment response and recurrence risk, helping personalize bladder cancer care.

New blood tests promise to detect malignancies before they’ve spread. But proving that these tests actually improve outcomes ...

Those who’d had both tubes removed had half the ovarian cancer risk of those who’d had only one tube out, as if the surgery were a preventive drug, more effective in its full dose.

BUFFALO, NY — June 13, 2025 — A new case report was published in Volume 12 of Oncoscience on May 22, 2025, titled “A rare case: Pure Sertoli cell tumor uncovered in atrophic ovary during ...

Promising ADC Efficacy in Resistant Ovarian Cancer: Lilly’s investigational FRα-targeting ADC, LY4170156, showed a 55% response rate at the proposed Phase II dose in platinum-resistant ovarian cancer, ...

Key Takeaways PHST001 targets CD24, a protein that helps tumors evade immune destruction, potentially enhancing immune response against cancer cells. The FDA's fast track designation accelerates the ...

Credit: Kathleen Cho, M.D. A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway for new treatments.

Ovarian cancer has earned the terrifying nickname “the silent killer” because it’s notorious for causing vague, easily dismissed symptoms that women often attribute to stress, aging, or ...

Session ID: 2025-07-05:1e5f948cc61f5287739a3157 Player Element ID: vjs_video_3 ...

She met him at Tampa General Hospital. ”He said, 'Brenda, you've got ovarian cancer with a very large mass and we're going to have to do surgery,'" said Gotlen. She had stage 3C ovarian cancer.

They found that immune cell function was suppressed across cancer sites within individual patients, and in particular, the ascites microenvironment inhibited NK cells’ tumor killing abilities.